FDA Approves Wearable Cardioverter Defibrillator
The patch-based cardioverter defibrillator is approved for use in patients with a temporary elevated risk of sudden cardiac arrest.
The patch-based cardioverter defibrillator is approved for use in patients with a temporary elevated risk of sudden cardiac arrest.
Medtronic is recalling Cobalt/Crome implantable cardioverter defibrillators and cardiac resynchronization therapy defibrillators.
Approximately 70% of out-of-hospital cardiac arrests occur in private homes that don’t have an automated external defibrillator.
The patch-based cardioverter defibrillator is approved for use in patients with a temporary elevated risk of sudden cardiac arrest.
FDA has changed the deadline for filing PMA applications for previously cleared AED accessories in response to the impact from COVID-19.
Read MoreA formalized protocol to transfer AED data upon hospital arrival for cardiac arrest patients may help staff decision-making and lessen the strain on hospital resources.
Read MoreRoyal Philips has launched a wireless remote monitoring and defibrillator solution (Tempus ALS) for pre-hospital settings in the United States.
Read MorePhilips has resumed the manufacturing and shipping of external defibrillators for the United States, following FDA notification that the injunction prohibiting those activities has been lifted.
Read MoreThe defibrillators market is forecast to reach $10.88 billion by 2022 from $9.32 billion in 2017 at a compound annual growth rate (CAGR) of 3.1%, according to market research firm ReportsnReports.
Read MoreBC Group, a company that manufactures, services, and sells biomedical testing equipment, has announced that its DA-2006-VL variable load box, an external load bank for the BC Biomedical line of defibrillator analyzers, has received FDA 510(k) clearance.
Read More